ArticleInfectious diseases and therapy2023

Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study.

Lorenzo Piemonti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.